NICE declines Yondelis for ovarian cancer
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, said it is still unable to recommend PharmaMar's Yondelis (trabectedin) to treat NHS patients with relapsed ovarian cancer because of a lack of data comparing it with the most commonly used treatments, particularly platinum-based chemotherapy.